Morning Buzz: Neos Therapeutics (NEOS), PayPal (PYPL), Facebook (FB), Yahoo (YHOO), Amazon (AMZN)

Shares of Neos Therapeutics, Inc. (NEOS) are spiking by nearly 62% to $15.20 in morning trading on Thursday after the company announced that the FDA approved Adzenys XR-ODT for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients six years and older. With this approval, Adzenys XR-ODT is the first and only extended-release orally disintegrating tablet for the treatment of ADHD.

PayPal Holdings, Inc. (PYPL) shares are up $1.96 to $33.55 in early trade after the company reported Q415 earnings results with EPS of $0.36 coming in 2c ahead of expectations while rev of $2.56 billion, up nearly 17%/YoY basis, topped $2.51 billion consensus.

PayPal guided Q1/16 revenues of $2.47 – $2.52 billion, as compared to analysts’ expectations of $2.48 billion. The management also gave its bottom line range of $0.34 – $0.36 per share, against projections of $0.35 per share. The online payment service provider also announced a $2 billion stock buyback program, a signal that management views ticker as undervalued at current levels.

Facebook, Inc. (FB) reported fourth quarter EPS of $0.79 after the closing bell Wednesday, compared to the consensus estimate of $0.68. Revenues increased 51.7% from last year to $5.84 billion. Analysts expected revenues of $5.37 billion.  Facebook’s strong numbers were driven by growth in mobile advertising, which now makes up roughly 80% of the social networking giant’s revenue.The stock is currently up $13.04 to $107.49 on more than 11 million shares.

Yahoo! Inc. (YHOO) shares climbed 2.86% to $30.54 in morning trading, following a Re/Code report detailing Yahoo’s restructuring plan.

Shares of Amazon (AMZN) are up nearly 5% this morning on a NYPost report saying the e-commerce giant is planning a subscription music service to compete with Spotify, Pandora, and others.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


*

This site uses Akismet to reduce spam. Learn how your comment data is processed.